PMID- 37835860
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231030
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 13
IP  - 19
DP  - 2023 Oct 3
TI  - Diagnostic Value of Labial Minor Salivary Gland Biopsy: Histological Findings of 
      a Large Sicca Cohort and Clinical Associations.
LID - 10.3390/diagnostics13193117 [doi]
LID - 3117
AB  - (1) Background: The aim of this study was to analyze labial minor salivary gland 
      biopsy (MSGB) findings of a large sicca cohort and to examine their associations 
      with Sjogren's syndrome (SS)-associated laboratory markers, phenotypic 
      characteristics and systemic manifestations. Moreover, we sought to explore the 
      ability of MSGB to identify SS patients among subjects with pre-diagnosed 
      fibromyalgia (FM). (2) Methods: Included were all patients of three rheumatology 
      departments having undergone a diagnostic MSGB within 9 years. Next to the 
      examination of histological and immunohistochemical findings, we focused on 
      activity and chronicity parameters of the underlying disease, autoantibodies, 
      presence of systemic and hematologic involvement, as well as chronic pain and SS 
      comorbidities. (3) Results: Among the 678 included patients, 306 (45.1%) had a 
      positive focus score (FS). The remaining patients (n = 372) served as control 
      subjects. There were significant correlations between FS and 
      hypergammaglobulinemia (p < 0.001), ANA and rheumatoid factor positivity (both; p 
      < 0.001), a weak significant correlation with erythrocyte sedimentation rate (rho 
      = 0.235; p < 0.001) and a negative correlation with nicotine use (p = 0.002). 
      Within the primary SS subgroup, FS was associated significantly with glandular 
      enlargement (p = 0.007) and systemic hematologic manifestations (p = 0.002). Next 
      to FS, CD20 cell staining showed an excellent diagnostic performance in the 
      diagnosis of SS by an area under the curve of 0.822 (95%CI 0.780-0.864; p < 
      0.001). Interestingly, 42.1% of all patients with fibromyalgia (FM) having 
      received an MSGB could be diagnosed with SS. (4) Conclusion: By examining one of 
      the largest cohorts in the literature, we could show that MSGB histological and 
      immunohistochemical findings not only play a key role in the classification and 
      diagnosis of SS but could also provide important information regarding SS 
      phenotype and systemic manifestations. Furthermore, MSGB may help differentiate 
      patients with FM from patients with subclinical SS who suffer primarily from 
      chronic pain.
FAU - Triantafyllias, Konstantinos
AU  - Triantafyllias K
AUID- ORCID: 0000-0001-8764-2636
AD  - Department of Rheumatology, Acute Rheumatology Center, 55543 Bad Kreuznach, 
      Germany.
AD  - Department of Internal Medicine I, Division of Rheumatology and Clinical 
      Immunology, University Medical Center, Johannes Gutenberg University, 55131 
      Mainz, Germany.
FAU - Bach, Mirjam
AU  - Bach M
AD  - Department of Internal Medicine I, Division of Rheumatology and Clinical 
      Immunology, University Medical Center, Johannes Gutenberg University, 55131 
      Mainz, Germany.
FAU - Otto, Mike
AU  - Otto M
AD  - Institute for Pathology, 54292 Trier, Germany.
FAU - Schwarting, Andreas
AU  - Schwarting A
AD  - Department of Rheumatology, Acute Rheumatology Center, 55543 Bad Kreuznach, 
      Germany.
AD  - Department of Internal Medicine I, Division of Rheumatology and Clinical 
      Immunology, University Medical Center, Johannes Gutenberg University, 55131 
      Mainz, Germany.
AD  - Department of Rheumatology, Karl-Aschoff Clinic, 55543 Bad Kreuznach, Germany.
LA  - eng
PT  - Journal Article
DEP - 20231003
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC10573002
OTO - NOTNLM
OT  - Sjogren's syndrome
OT  - chronic pain
OT  - focus score
OT  - immunohistochemistry
OT  - minor salivary gland biopsy
OT  - sicca
COIS- The authors declare no conflict of interest.
EDAT- 2023/10/14 10:47
MHDA- 2023/10/14 10:48
PMCR- 2023/10/03
CRDT- 2023/10/14 01:14
PHST- 2023/08/24 00:00 [received]
PHST- 2023/09/14 00:00 [revised]
PHST- 2023/09/27 00:00 [accepted]
PHST- 2023/10/14 10:48 [medline]
PHST- 2023/10/14 10:47 [pubmed]
PHST- 2023/10/14 01:14 [entrez]
PHST- 2023/10/03 00:00 [pmc-release]
AID - diagnostics13193117 [pii]
AID - diagnostics-13-03117 [pii]
AID - 10.3390/diagnostics13193117 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2023 Oct 3;13(19):3117. doi: 10.3390/diagnostics13193117.